PROFID EHRA trial aims to personalize the prevention of sudden cardiac death after myocardial infarction

The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient.

Spicing up the fight: Saffron’s powerful impact on prostate cancer revealed

Saffron-treated prostate cancer (PCa) cells.

January 3, 2024

The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits – Psychedelic Alpha

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already

September 30, 2024

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase | Psychedelic Invest

TORONTO, May 14, 2024–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company“), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new

May 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.